Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host.
Neoplastic disease is a frequent complication in patients with acquired immunodeficiency disease (AIDS) and other immunodeficiencies. Many such neoplasms are caused by either Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpes virus (KSHV). The treatment of such patients can be challenging. At the same time, the viral origin of these tumors offers targets to develop pathogenesis-based therapies. Standard therapies for these diseases involve such approaches as treating the underlying immunodeficiency, cytotoxic chemotherapy, and immunologic antitumor therapy. Novel therapy approaches include specific immune therapy and anti-angiogenesis approaches, now under development.
Little
Richard F
RF
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Yarchoan
Robert
R
D018142:Gammaherpesvirinae; D006566:Herpesviridae Infections / Q000139:chemically induced / Q000150:complications* / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy / Q000821:virology*; D014412:Tumor Virus Infections / Q000139:chemically induced / Q000150:complications / Q000821:virology